论文部分内容阅读
目的 探讨化疗联合放疗对晚期肺腺癌预后的影响。方法 选择 80例晚期肺腺癌 ,其中 45例采用MVP方案 (丝裂霉素、长春花碱酰胺、顺铂 )化疗 1～ 2周期后给予局部放疗 ,放疗的同时或结束后再行化疗 2～ 4周期 ;35例单纯采用MVP方案化疗 4～ 6周期。结果 放化组总缓解率为 6 6 7% ,中位生存期 19 1个月 ,其 1、2、3年生存率分别为 6 4 4%、33 3 %、15 5 %。单化组总缓解率为34 3 % ,中位生存期 9 2个月 ,其 1、2、3年生存率分别为 40 %、11 4%、0 %。放化组疗效优于单化组 (P <0 0 5 )。两组的毒副作用无统计学差异 (P >0 0 5 )。结论 MVP化疗联合放疗能改善晚期肺腺癌患者生存质量 ,延长生存期 ,提高生存率。
Objective To investigate the effect of chemotherapy combined with radiotherapy on the prognosis of advanced lung adenocarcinoma. Methods Eighty patients with advanced adenocarcinoma of the lung were selected. Forty-five patients were treated with MVP (mitomycin, vinblastine, cisplatin) chemotherapy for one to two cycles after radiotherapy. Radiotherapy was given concurrently with or after radiotherapy for 2 ~ 4 cycles; 35 cases of simple chemotherapy with MVP 4 to 6 cycles. Results The total remission rate of radiotherapy and chemotherapy group was 66.7%, and the median survival time was 19.1 months. The 1, 2, 3 year survival rates were 64.4%, 33.3% and 15.5% respectively. The overall response rate was 34.3% in the single group and 92% in the median group. The 1, 2, 3-year survival rates were 40%, 114% and 0% respectively. Radiotherapy group was better than the single group (P <0 05). There was no significant difference in the side effects between the two groups (P> 0.05). Conclusion MVP chemotherapy combined with radiotherapy can improve the quality of life, prolong the survival and improve the survival rate of patients with advanced lung adenocarcinoma.